TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06565481

Intervention type: OTHER
Group type: OTHER
Intervention: Measurement Properties (Reliability and Validity) of a Set of Assessments evaluating Physical Function in adult Participants with Hemophilia
Description: This study evaluates the reliability (Test-Retest) of six health related instruments that assess physical function in people with hemophilia: Short Physical Performance Battery, Unipedal Stance Test, Four Square Step Test, Timed up and Go, 1 kg Arm Lift Test, 30 Second Chair Stand Test. This study is needed to determine the psychometric properties of these six assessments. Validity of these test will be determined with the Short Form 36, the Hemophilia Activities List and the Hemophilia Joint Health Score Methodology: Reliability (Test re-test study and validity (cross sectional study) of the six tests reported in patients with hemophilia.~This intervention contains physiotherapie assessments, however, no drugs nor medical devices.
Study: NCT06124807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3305677
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3305677
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3305677
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study: NCT06114940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: 240mg, IV (in the vein) on on day 1 of 3-week, 6-week and 9-week for a total of 3 doses prior to partial nephrectomy or radical nephrectomy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: 20 mg by mouth once each day for 12 weeks prior to nephrectomy
Study: NCT06539741

Intervention type: DRUG
Intervention: Ibuprofen 400 mg
Description: 400 mg by mouth every 4 hours for 2 days after third molar extraction and then as needed for pain up to 7 days after third molar extraction

Intervention type: DRUG
Intervention: Ibuprofen 400 mg
Description: 400 mg by mouth every 4 hours for 2 days after third molar extraction and then as needed for pain up to 7 days after third molar extraction

Intervention type: DRUG
Intervention: Acetaminophen 500mg
Description: 500 mg by mouth every 4 hours for 2 days after third molar extraction and then as needed for pain up to 7 days after third molar extraction

Intervention type: DRUG
Intervention: Acetaminophen 500mg
Description: 500 mg by mouth every 4 hours for 2 days after third molar extraction and then as needed for pain up to 7 days after third molar extraction

Intervention type: DRUG
Intervention: OxyCODONE 5 mg Oral Tablet
Description: 5 mg by mouth every 6 hours as needed for pain
Study: NCT06029322

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Socket seal after alveolar ridge preservation
Description: Socket seal is performed after ARP. Using a collagen matrix or membrane the socket is sealed, at the control (membrane) site a small pouch is made at the buccal and lingual aspect. Monofilament sutures are used to secure the respective material in place.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Socket seal after alveolar ridge preservation
Description: Socket seal is performed after ARP. Using a collagen matrix or membrane the socket is sealed, at the control (membrane) site a small pouch is made at the buccal and lingual aspect. Monofilament sutures are used to secure the respective material in place.
Study: NCT06089538

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: mEEG battery
Description: The 2 groups will be assessed twice : in the acute phase of acute respiratory distress syndrome (ARDS) at patient's bedside in the intensive care unit (ICU) using an mEEG battery (electrophysiological acquisition at rest and during complex cognitive stimulation), and a simple clinical neuropsychological assessment ; 6 months ± 2 weeks later using the same mEEG battery and a multi-domain clinical neurocognitive and psychological assessment battery

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: mEEG battery
Description: The 2 groups will be assessed twice : in the acute phase of acute respiratory distress syndrome (ARDS) at patient's bedside in the intensive care unit (ICU) using an mEEG battery (electrophysiological acquisition at rest and during complex cognitive stimulation), and a simple clinical neuropsychological assessment ; 6 months ± 2 weeks later using the same mEEG battery and a multi-domain clinical neurocognitive and psychological assessment battery
Study: NCT06191900

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous tumor infiltrating lymphocyte injection（GT201）
Description: GT201 treatment for advanced gynecological tumors (advanced cervical cancer)
Study: NCT06266052

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Triangular Flap
Description: Triangular flap is a type of flap that is made in the retromolar region, from the distal of the 2nd molar tooth towards the ramus and up to the distal gingival sulcus of the 2nd molar, and includes a vertical releasing incision added from the distobuccal sulcus of the 2nd molar tooth. The auxiliary vertical incision made in this flap type allows the wound to be closed without tension.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Berwick Flap
Description: Berwick described a type of flap whose base is in the distolingual direction of the second molar tooth, in which the tongue-shaped vestibular wing extends to the buccal part of the mandible. In this modification, the incision line is not over the bone defect created by the extraction.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Saurez Flap
Description: In the modified flap type he used, Suarez combined the crestal incision (marginal incision) from the distobuccal corner of the second molar tooth, following the line where the retromolar area meets the buccal bone, with a releasing incision made at the mesial and distal ends of the incision.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Heitz Flap
Description: Heitz used the incision line extending from the distobuccal corner of the 2nd molar tooth to the buccal face of the 2nd molar tooth and downwards, by rotating it towards the angulus mandible on the buccal bone.
Study: NCT05738525

Intervention type: DEVICE
Intervention: APD-RPM
Description: APD mode is recommended but not limited to continuous circulating peritoneal dialysis (CCPD); (2) Dialysis dose ranges from 5 to 10 liters per day and depends on previous APD prescription and dialysis adequacy; (3) Glucose concentration starts from low concentration (1.5%) and depends on previous dialysis prescription.~Remote monitoring includes dynamic changes of the overall treatment situation, warning or any abnormal notes, and drainage, retention and duration of APD per day.
Study: NCT05642494

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SDF
Description: Silver Diamine Fluoride 38% (Applied bianually)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SDF
Description: Silver Diamine Fluoride 38% (Applied bianually)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NaF
Description: Sodium Fluoride Varnish (5%) (Applied at baseline and after 3 months)
Study: NCT04420364

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maintenance or reduction of immunosuppression
Description: Maintenance versus reduction of immunosuppression

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Maintenance or reduction of immunosuppression
Description: Maintenance versus reduction of immunosuppression
Study: NCT05116774

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCX9930
Description: Administered orally at a dose of 200 mg twice daily for the first 2 weeks, then 400 mg twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eculizumab
Description: Administered by intravenous infusion per current dose regimen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ravulizumab
Description: Administered as intravenous infusion per current dose regimen
Study: NCT06298071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SIBP-R002
Description: Injection; strength: 4mg. Each group consists of 12 participants. Firstly, 4 sentinel participants were enrolled in the single dose phase of peruricase for injection and methotrexate. After the sentinel participants completed a 5-day safety observation of the single dose, the remaining 8 participants in this group can be enrolled simultaneously. If there are no special circumstances, the participants in this group will enter the multi-dose stage of peruricase for injection combined with methotrexate within 2-4 weeks after completing a single dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SIBP-R002
Description: Injection; strength: 8mg. Each group consists of 12 participants. Firstly, 4 sentinel participants were enrolled in the single dose phase of peruricase for injection and methotrexate. After the sentinel participants completed a 5-day safety observation of the single dose, the remaining 8 participants in this group can be enrolled simultaneously. If there are no special circumstances, the participants in this group will enter the multi-dose stage of peruricase for injection combined with methotrexate within 2-4 weeks after completing a single dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SIBP-R002
Description: Injection; strength: 12mg. Each group consists of 12 participants. Firstly, 4 sentinel participants were enrolled in the single dose phase of peruricase for injection and methotrexate. After the sentinel participants completed a 5-day safety observation of the single dose, the remaining 8 participants in this group can be enrolled simultaneously. If there are no special circumstances, the participants in this group will enter the multi-dose stage of peruricase for injection combined with methotrexate within 2-4 weeks after completing a single dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Combination drugs: Methotrexate, dose15 mg, oral.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Combination drugs: Methotrexate, dose15 mg, oral.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Combination drugs: Methotrexate, dose15 mg, oral.
Study: NCT05297032

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Quercetin Phytosome
Description: All participants will ingest 1 capsule of Quercetin Phytosome (250 mg) three times daily with meals for 90 days.
Study: NCT05000840

Intervention type: BEHAVIORAL
Intervention: Enrollment in existing SDRI diabetes education programs
Description: Education will be based on a modification of the existing Ocho Pasos education program provided by SDRI.
Study: NCT06214208

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcutaneous Spinal Stimulation
Description: Transcutaneous spinal stimulation will be delivered for 30 minutes using biphasic pulses. A single cathode electrode will be placed over the skin of the back spine at the T11/T12 spinous interspace. Two reference electrodes will be placed over the stomach. Stimulation intensity will be set to 0.8x reflex threshold, as determined by posterior root muscle reflex testing before the intervention. Treatments will be a minimum of 72 hours apart.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcutaneous Spinal Stimulation
Description: Transcutaneous spinal stimulation will be delivered for 30 minutes using biphasic pulses. A single cathode electrode will be placed over the skin of the back spine at the T11/T12 spinous interspace. Two reference electrodes will be placed over the stomach. Stimulation intensity will be set to 0.8x reflex threshold, as determined by posterior root muscle reflex testing before the intervention. Treatments will be a minimum of 72 hours apart.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcutaneous Spinal Stimulation
Description: Transcutaneous spinal stimulation will be delivered for 30 minutes using biphasic pulses. A single cathode electrode will be placed over the skin of the back spine at the T11/T12 spinous interspace. Two reference electrodes will be placed over the stomach. Stimulation intensity will be set to 0.8x reflex threshold, as determined by posterior root muscle reflex testing before the intervention. Treatments will be a minimum of 72 hours apart.
Study: NCT04491175

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: M-Stim
Description: The casing for the device is a 54 belt with 3-button haptic controller for on-off, therapy cycles(8) and intensity(5) levels.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TENS
Description: LG SMART TENS stimulator is a portable electrotherapy devcie featuring transcutaneous electrical nerve stimulation (TENS) therapeutic device, which is used for pain relief. The stimulator sends a gentle electrical current to underlying nerves and muscle groups via electrodes applied on the skin. The parameters of the device are controlled by buttons on a controller with an adjustable intensity level.
Study: NCT05405309

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RP-3500
Description: RP-3500 is a highly potent and selective Ataxia telangiectasia and Rad3 related inhibitor (ATRi) and has demonstrated significant preclinical activity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RP-3500
Description: RP-3500 is a highly potent and selective Ataxia telangiectasia and Rad3 related inhibitor (ATRi) and has demonstrated significant preclinical activity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RP-3500
Description: RP-3500 is a highly potent and selective Ataxia telangiectasia and Rad3 related inhibitor (ATRi) and has demonstrated significant preclinical activity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RP-3500
Description: RP-3500 is a highly potent and selective Ataxia telangiectasia and Rad3 related inhibitor (ATRi) and has demonstrated significant preclinical activity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RP-3500
Description: RP-3500 is a highly potent and selective Ataxia telangiectasia and Rad3 related inhibitor (ATRi) and has demonstrated significant preclinical activity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RP-3500
Description: RP-3500 is a highly potent and selective Ataxia telangiectasia and Rad3 related inhibitor (ATRi) and has demonstrated significant preclinical activity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib is an oral poly (adenosine diphosphate-ribose) polymerase inhibitor (PARPi) that inhibits PARP's function by competitively binding to the Nicotinamide adenine dinucleotide (NAD+) binding site, which PARP requires as a cofactor to operate.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib is an oral poly (adenosine diphosphate-ribose) polymerase inhibitor (PARPi) that inhibits PARP's function by competitively binding to the Nicotinamide adenine dinucleotide (NAD+) binding site, which PARP requires as a cofactor to operate.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib is an oral poly (adenosine diphosphate-ribose) polymerase inhibitor (PARPi) that inhibits PARP's function by competitively binding to the Nicotinamide adenine dinucleotide (NAD+) binding site, which PARP requires as a cofactor to operate.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib is an oral poly (adenosine diphosphate-ribose) polymerase inhibitor (PARPi) that inhibits PARP's function by competitively binding to the Nicotinamide adenine dinucleotide (NAD+) binding site, which PARP requires as a cofactor to operate.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib is an oral poly (adenosine diphosphate-ribose) polymerase inhibitor (PARPi) that inhibits PARP's function by competitively binding to the Nicotinamide adenine dinucleotide (NAD+) binding site, which PARP requires as a cofactor to operate.
Study: NCT05392452

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CamAPS HX
Description: Fully automated closed-loop subcutaneous insulin delivery system. A model predictive controller modulates insulin delivery every 10-12 minutes based on interstitial glucose measurements.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard insulin therapy
Description: Standard insulin therapy according to local clinical practice.
Study: NCT04638439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P1101 + Nivolumab + Entecavir
Description: P1101 (Ropeginterferon alfa-2b) 450 µg subcutaneously (SC) Q2W for 6 doses (12 weeks), followed by 0.3 mg/kg Nivolumab for 6 doses (12 weeks), with a follow up of 24 weeks. All patients will also receive Entecavir 0.5 mg QD from Day 1 to Follow-up 24.
Study: NCT05966571

Intervention type: PROCEDURE
Intervention: Ovary Biopsie
Description: Ovarian biopsy will be performed on patients meeting the inclusion criteria undergoing surgery for other reasons. Ovarian biopsy will be of a few millimeters in size and taken on only one of the ovaries.
Study: NCT05437809

Intervention type: OTHER
Group type: OTHER
Intervention: Intake of nutritionally diverse ultra-processed foods
Description: All participants will attend four food consumption assessment visits where, at each visit, they will be asked to consume a standardized snack portion of: 1) ultra-processed foods (UPFs) high in both fat and refined carbohydrates (UPF+FRC), 2) UPF high in fat (UPF+F), 3) UPF high in refined carbohydrates (white flour, sugar) (UPF+RC), or 4) minimally processed foods. The order of the four food consumption assessment visits will be randomized and counterbalanced across participants, who will each consume all the test snacks across the four appointments.
Study: NCT05288127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: The recommended dose is 1 mg talazoparib once daily. Patients should be treated until disease progression or unacceptable toxicity occurs. Daily dosing of talazoparib can be interrupted for recovery from toxicity for up to 28 days. For interruptions longer than 28 days, treatment at the same or a reduced dose can be considered based on the if evidence of response or clinical benefit to talazoparib is noted.~Missing dose If the patient vomits or misses a dose, an additional dose should not be taken. The next prescribed dose should be taken at the usual time.~Dose adjustments:~To manage adverse drug reactions, interruption of treatment or dose reduction based on severity and clinical presentation should be considered.
Study: NCT04807270

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intra-articular T-LAB / PRP KIT injection
Description: Intra-articular 3 ml T-LAB / PRP KIT injection in 3 sessions will be applied. As a home exercise program, hamstring and quadriceps stretching, quadriceps isometric strengthening, short arc terminal extension exercises will be given at least three days a week with 3 sets of 10 repetitions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intra-articular T-LAB / PRP INJECTION SYRINGE injection
Description: Intra-articular 3 ml T-LAB / PRP INJECTION SYRINGE injection in 3 sessions will be applied. As a home exercise program, hamstring and quadriceps stretching, quadriceps isometric strengthening, short arc terminal extension exercises will be given at least three days a week with 3 sets of 10 repetitions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intra-articular SALINE injection
Description: Intra-articular 3 ml SALINE injection in 3 sessions will be applied. As a home exercise program, hamstring and quadriceps stretching, quadriceps isometric strengthening, short arc terminal extension exercises will be given at least three days a week with 3 sets of 10 repetitions.
Study: NCT04873310

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Triple P online with professional support
Description: The psychologist in charge will have the role of monitoring the autonomous work of the participants during the 8 sessions. The psychologist in charge will also verify that the participants are able to complete the online modules week by week, that they understand the contents taught in the module and that they are practicing the tasks and exercises assigned in each of the modules; in addition to generating an action plan in case the participants are not adhering week by week to the self-administration of the program. The follow-up and contact with the families will be carried out by phone and through a weekly email-type messaging system, implemented within the same platform on which the program material is found

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Triple P online without professional support
Description: The role of the psychologist in charge will be to keep the platform updated so that the person who self-administers the intervention does not have technical problems associated with the platform.
Study: NCT05375201

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VR skateboarding training
Description: The virtual reality skateboard training (VR-skate) is used treadmill-based training. Virtual reality system is integrated into the split-belt treadmill for VR-skate. Participants slide the swing leg (sliding leg) along with the moving treadmill belt at a comfortable speed (same as walking speed).
Study: NCT06639607

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEP-CMV vaccine
Description: Intra-dermally administered half in the RIGHT groin and half in the LEFT groin.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEP-CMV vaccine
Description: Intra-dermally administered half in the RIGHT groin and half in the LEFT groin.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEP-CMV vaccine
Description: Intra-dermally administered half in the RIGHT groin and half in the LEFT groin.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEP-CMV vaccine
Description: Intra-dermally administered half in the RIGHT groin and half in the LEFT groin.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetanus booster
Description: Td 5 flocculation units, Lf
Study: NCT06094491

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Group Visit
Description: Group visits must have these core components: diabetes education, group social support and goal setting.